DLD Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

DLD Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$380K	Buy	+15,000	New	+$330K	0.03%	272
2020 Q1	–	Sell	-217,600	Closed	-$9.31M	–	80
2019 Q4	$9.31M	Sell	217,600 -45,400	-17%	-$1.98M	0.5%	27
2019 Q3	$9.46M	Buy	+263,000	New	+$7.97M	0.48%	24

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

DLD Asset Management's ACAD Position: Q2 2026 in Review

DLD Asset Management opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 10,000 shares worth $253K. The stake represents 0.02% of the portfolio and ranks #285 among its holdings.

352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

DLD Asset Management held 10,000 shares of Acadia Pharmaceuticals worth $253K as of Q2 2026.
Acadia Pharmaceuticals was a new DLD Asset Management position in Q2 2026.
Acadia Pharmaceuticals made up 0.02% of DLD Asset Management's portfolio in Q2 2026, its #285 holding.
352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on DLD Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.